Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Petros Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
9.56
7.81
5.99
5.82
5.11
Cost of revenue
4.05
1.6
2.29
1.63
1.21
Gross profit
5.51
6.21
3.7
4.19
3.9
Research and development
0.46
1.79
1.74
2.41
2.62
Selling, general and administrative
15.7
15.6
12.2
9.26
4.63
4.64
Operating expenses
22.8
24.3
23.6
17.8
4.63
4.64
Operating income
-17.3
-18
-19.9
-13.6
-4.63
-4.64
Interest expense
3.05
0.37
0.6
0.54
0.56
Interest income
0.01
Other non-operating income
-0.12
5.45
3.92
0.14
Pre-tax income
-22
-8.99
-20
-8.16
-0.71
-4.5
Income tax
-1.43
0
0
0
0
Income from continuing operations
-0.71
-4.5
Net income
-20.6
-8.99
-20
-8.16
-14.3
1.91
EBITDA
-10.6
-11.2
-14.3
-10.3
-1.8
EPS, basic
-956.36
-206.18
-241.91
-158.69
-83.47
-1.56
EPS, diluted
-956.36
-206.18
-241.91
-158.69
-83.47
-1.56
Shares, basic (weighted)
0.02
0.04
0.08
0.09
0.32
28.1
Shares, diluted (weighted)
0.02
0.04
0.08
0.09
0.32
28.1
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
17.1
23.8
9.43
13.3
1.72
5.14
Receivables
5.15
2.46
2.11
2.23
0.42
Inventory
0.76
0.52
1.82
1.61
1.35
Other current assets
0.11
0.11
0.14
0.11
0.01
0.03
Total current assets
25.9
30.5
14.7
20.4
7.29
5.16
Property, plant and equipment
0.06
0.05
0.04
0.03
0.02
Lease right-of-use assets
0.58
0.48
0.36
0.23
0.11
Intangible assets
32.2
25.3
12.2
8.97
3.2
Other non-current assets
0.58
0.48
0.36
Total assets
69.9
67.4
32.4
33.8
10.6
5.16
Accounts payable
4.56
1.81
1.71
0.76
0.08
Accrued liabilities
14.7
12
3.63
5.36
0.1
0.14
Short-term debt
7.18
Total current liabilities
41.9
31
7.07
10.8
18
2.29
Long-term debt
8.39
6.86
Lease liabilities
0.53
0.41
0.26
0.14
0.08
Other non-current liabilities
0.6
0.41
0.26
0.14
0.08
Total liabilities
52.4
31.8
15.7
21.3
18.1
2.29
Total debt
7.18
Paid-in capital
79.2
106
107
111
106
114
Retained earnings
-61.7
-70.7
-90.7
-98.9
-113
-111
Shareholders' equity
17.5
35.5
16.7
12.1
-7.47
2.87
Total equity
17.5
35.5
16.7
12.1
-7.47
2.87
Total liabilities and equity
69.9
67.4
32.4
33.8
10.6
5.16
Shares outstanding
0.04
0.08
0.08
0.12
0.42
42.3
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-20.6
-8.99
-20
-8.16
-14.3
1.91
Depreciation and amortization
6.66
6.88
5.6
3.28
2.83
Stock-based compensation
1.31
1.2
0.42
0.2
0.3
Deferred income tax
-1.43
0
0
0
0
Change in receivables
-2.75
2.55
0.52
-0.14
1.82
Change in inventory
0.73
0.41
-0.84
0.27
0.31
Change in payables
2.22
-1.05
-2.75
-0.09
0.35
-0.68
Cash from operations
-15.3
-11.9
-12.8
-7.63
-2.6
-6.73
Capital expenditures
-0
-0.02
Cash from investing
-0
-0.02
Debt repaid
-6.18
-6.65
Stock issued
21.7
Cash from financing
30.3
18.6
-1.62
11.5
-7
8.16
Net change in cash
15
6.71
-14.4
3.91
-9.63
1.43
Free cash flow
-15.3
-2.63
Interest paid
1.19
0.42
0.6
0.54
0.23
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.00 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-456.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-90.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value CAGR, 3y
-44.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-30.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-51.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-45.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-40.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
8,642.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
597.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
319.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.25x
Current assets / current liabilities.
Quick ratio
1.23x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.23x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.08
Cash from operations / diluted weighted shares.
Book value per share
$0.02
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.24x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.24x
Market cap / tangible book value, when positive.
Earnings yield
-1,889.0%
Net income / market cap (the inverse of P/E).
Was Petros Pharmaceuticals, Inc. profitable in fiscal 2025?
Yes. Net income was $1.9M, a net margin of -.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.